Detailed Mechanism Funding and Narrative

Years of mechanism: 2013 2014 2015 2016 2017 2018 2019 2020

Details for Mechanism ID: 14507
Country/Region: Zambia
Year: 2014
Main Partner: FHI 360
Main Partner Program: NA
Organizational Type: NGO
Funding Agency: USDOD
Total Funding: $0 Additional Pipeline Funding: $1,888,509

NOTE: The following is taken from summaries released by PEPFAR on the PEPFAR Data Dashboard. They are incomplete summary paragraphs only and do not contain the full mechanism details. When the full narratives are released, we will update the mechanism pages accordingly.

REDACTED awarded by the Department of Defense HIV/AIDS Prevention Program (DHAPP) to FHI360 to REDACTED HIV Prevention, Care and Treatment project in Zambia, targeting the defense forces. The ZDFPCT project aims to support expansion of quality HIV/AIDS services among the Zambia Defense forces (ZDF) through the following Objectives:

1. To strengthen and scale up HIV/AIDS prevention, care and treatment services in the ZDF health facilities (i.e. ZNS, Zambia Air force (ZAF) and Zambian Army (ZA);

2. To provide a comprehensive HIV/AIDS service package that includes strengthening of the laboratory and pharmacy support services and networks within the ZDF medical services; and

3. Increase the capacity for the Zambia Defense Force Medical Services to perform and manage HIV/AIDS technical functions in a sustainable manner. The support provided to the ZDF includes: capacity building; renovations; procurement of laboratory equipment and other basic equipment; and technical assistance to ensure provision of quality services based on nationally approved guidelines and standard operating procedures. Support towards implementation of nationally approved Quality Assurance/Quality Improvement (QA/QI) system and tools ensure sustainability of quality services.

Mechanism Allocation by Budget Code for Selected Year
Care: Adult Care and Support (HBHC) $0
Care: Pediatric Care and Support (PDCS) $0
Laboratory Infrastructure (HLAB) $0
Strategic Information (HVSI) $0
Health Systems Strengthening (OHSS) $0
Biomedical Prevention: Voluntary Medical Male Circumcision (CIRC) $0
Testing: HIV Testing and Counseling (HVCT) $0
Biomedical Prevention: Prevention of Mother to Child Transmission (MTCT) $0
Treatment: Adult Treatment (HTXS) $0
Treatment: Pediatric Treatment (PDTX) $0
Mechanism Target Information

Since COP2014, PEPFAR no longer produces narratives for every mechanism it funds. However, PEPFAR has now included performance targets or indicator information for each mechanism based on the Monitoring, Evaluation, and Reporting (MER) system. The MER guidance is available on PEPFAR's website https://www.pepfar.gov/reports/guidance/. Note that COP years 2014-2015 were under a previous version of the MER system and the indicators and definitions may have changed as of the new 2.0 guidance.

MER Indicator MER description Target Fiscal Year Target
CARE_CURR Age/sex: <1 Female 2015 54
CARE_CURR Age/sex: <1 Male 2015 12
CARE_CURR Age/sex: 1-4 Female 2015 138
CARE_CURR Age/sex: 1-4 Male 2015 30
CARE_CURR Age/sex: 10-14 Female 2015 684
CARE_CURR Age/sex: 10-14 Male 2015 138
CARE_CURR Age/sex: 15-19 Female 2015 708
CARE_CURR Age/sex: 15-19 Male 2015 138
CARE_CURR Age/sex: 20-24 Female 2015 1,038
CARE_CURR Age/sex: 20-24 Male 2015 216
CARE_CURR Age/sex: 25-49 Female 2015 2,070
CARE_CURR Age/sex: 25-49 Male 2015 402
CARE_CURR Age/sex: 5-9 Female 2015 192
CARE_CURR Age/sex: 5-9 Male 2015 42
CARE_CURR Age/sex: 50+ Female 2015 108
CARE_CURR Age/sex: 50+ Male 2015 30
CARE_CURR Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Female 2015 1,068
CARE_CURR Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Male 2015 222
CARE_CURR Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Female 2015 3,924
CARE_CURR Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Male 2015 786
CARE_CURR Number of HIV positive adults and children who received at least one of the following during the reporting period: clinical assessment (WHO staging) OR CD4 count OR viral load 2015 6,000
CARE_CURR Sum of Age/Sex disaggregates 2015 6,000
CARE_CURR Sum of Aggregated Age/Sex disaggregates 2015 6,000
CARE_SITE Number of PEPFAR-supported HIV clinical care sites at which at least 80% of PLHIV received all of the following during the reporting period: 1) clinical assessment (WHO staging) OR CD4 count OR viral load, AND 2) TB screening at last visit, AND 3) if eligible, cotrimoxazole 2015 30
CARE_SITE Total number of PEPFAR supported sites providing clinical care services 2015 35
GEND_GBV Age: 0-9 2015 50
GEND_GBV Age: 10-14 2015 200
GEND_GBV Age: 15-17 2015 100
GEND_GBV Age: 18-24 2015 100
GEND_GBV Age: 25+ 2015 50
GEND_GBV By PEP service provision (related to sexual violence services provided) 2015 100
GEND_GBV By type of service: Physical and/or Emotional Violence (Other Post-GBV Care) 2015 200
GEND_GBV By type of service: Sexual Violence (Post-Rape Care) 2015 300
GEND_GBV Number of people receiving post-GBV care 2015 500
GEND_GBV Sex: Female 2015 495
GEND_GBV Sex: Male 2015 5
GEND_GBV Sum of Age disaggregates 2015 500
GEND_GBV Sum of Sex disaggregates 2015 500
HTS_TST Age/sex: <1 Female 2015 270
HTS_TST Age/sex: <1 Female 2015 270
HTS_TST Age/sex: <1 Male 2015 60
HTS_TST Age/sex: <1 Male 2015 60
HTS_TST Age/sex: 1-4 Female 2015 690
HTS_TST Age/sex: 1-4 Female 2015 690
HTS_TST Age/sex: 1-4 Male 2015 150
HTS_TST Age/sex: 1-4 Male 2015 150
HTS_TST Age/sex: 10-14 Female 2015 2,820
HTS_TST Age/sex: 10-14 Female 2015 2,820
HTS_TST Age/sex: 10-14 Male 2015 1,290
HTS_TST Age/sex: 10-14 Male 2015 1,290
HTS_TST Age/sex: 15-19 Female 2015 2,640
HTS_TST Age/sex: 15-19 Female 2015 2,640
HTS_TST Age/sex: 15-19 Male 2015 1,590
HTS_TST Age/sex: 15-19 Male 2015 1,590
HTS_TST Age/sex: 20-24 Female 2015 3,390
HTS_TST Age/sex: 20-24 Female 2015 3,390
HTS_TST Age/sex: 20-24 Male 2015 2,880
HTS_TST Age/sex: 20-24 Male 2015 2,880
HTS_TST Age/sex: 25-49 Female 2015 7,350
HTS_TST Age/sex: 25-49 Female 2015 7,350
HTS_TST Age/sex: 25-49 Male 2015 5,010
HTS_TST Age/sex: 25-49 Male 2015 5,010
HTS_TST Age/sex: 5-9 Female 2015 960
HTS_TST Age/sex: 5-9 Female 2015 960
HTS_TST Age/sex: 5-9 Male 2015 210
HTS_TST Age/sex: 5-9 Male 2015 210
HTS_TST Age/sex: 50+ Female 2015 540
HTS_TST Age/sex: 50+ Female 2015 540
HTS_TST Age/sex: 50+ Male 2015 150
HTS_TST Age/sex: 50+ Male 2015 150
HTS_TST Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Female 2015 4,740
HTS_TST Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Male 2015 1,710
HTS_TST Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Female 2015 13,920
HTS_TST Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Male 2015 9,630
HTS_TST Aggregated Age/sex: <15 Female 2015 4,740
HTS_TST Aggregated Age/sex: <15 Male 2015 1,710
HTS_TST Aggregated Age/sex: 15+ Female 2015 13,920
HTS_TST Aggregated Age/sex: 15+ Male 2015 9,630
HTS_TST By Test Result: Negative 2015 25,800
HTS_TST By Test Result: Negative 2015 25,800
HTS_TST Number of individuals who received T&C services for HIV and received their test results during the past 12 months 2015 30,000
HTS_TST Number of individuals who received T&C services for HIV and received their test results during the past 12 months 2015 30,000
HTS_TST Sum of Age/Sex disaggregates 2015 30,000
HTS_TST Sum of Age/Sex disaggregates 2015 30,000
HTS_TST Sum of Aggregated Age/Sex <15 2015 6,450
HTS_TST Sum of Aggregated Age/Sex <15 2015 6,450
HTS_TST Sum of Aggregated Age/Sex 15+ 2015 23,550
HTS_TST Sum of Aggregated Age/Sex 15+ 2015 23,550
HTS_TST Sum of Aggregated Age/Sex disaggregates 2015 30,000
HTS_TST Sum of Aggregated Age/Sex disaggregates 2015 30,000
HTS_TST Sum of Test Result disaggregates 2015 30,000
HTS_TST Sum of Test Result disaggregates 2015 30,000
HTS_TST_POS By Test Result: Positive 2015 4,200
HTS_TST_POS By Test Result: Positive 2015 4,200
LAB_CAP By clinical laboratories 2015 12
LAB_CAP By site support type: Direct Service Delivery (DSD) 2015 12
LAB_CAP Number of PEPFAR-supported testing facilities with capacity to perform clinical laboratory tests 2015 12
LAB_CAP Sum of Site Support Type disaggregates 2015 12
PMTCT_ARV Life-long ART (including Option B+) 2015 400
PMTCT_ARV Maternal AZT (prophylaxis component of WHO Option A during pregnancy and delivery) 2015 30
PMTCT_ARV Number of HIV- positive pregnant women identified in the reporting period (including known HIV-positive at entry) 2015 500
PMTCT_ARV Number of HIV-positive pregnant women who received antiretrovirals to reduce risk of mother-to-child-transmission (MTCT) during pregnancy and delivery 2015 400
PMTCT_ARV Single-dose nevirapine (with or without tail) 2015 18
PMTCT_ARV Sub-Disag of Life-long ART: Already on treatment at the beginning of the current pregnancy 2015 300
PMTCT_ARV Sub-Disag of Life-long ART: Newly initiated on treatment during the current pregnancy 2015 100
PMTCT_ARV Sum of New and Current disaggregates 2015 400
PMTCT_ARV Sum of Regimen Type disaggregates 2015 448
PMTCT_ARV_NGI Life-long ART (including Option B+) 2015 400
PMTCT_ARV_NGI Maternal AZT (prophylaxis component of WHO Option A during pregnancy and delivery) 2015 30
PMTCT_ARV_NGI Number of HIV- positive pregnant women identified in the reporting period (including known HIV-positive at entry) 2015 500
PMTCT_ARV_NGI Number of HIV-positive pregnant women who received antiretrovirals to reduce risk of mother-to-child-transmission (MTCT) during pregnancy and delivery 2015 400
PMTCT_ARV_NGI Single-dose nevirapine (with or without tail) 2015 18
PMTCT_ARV_NGI Sub-Disag of Life-long ART: Already on treatment at the beginning of the current pregnancy 2015 300
PMTCT_ARV_NGI Sub-Disag of Life-long ART: Newly initiated on treatment during the current pregnancy 2015 100
PMTCT_ARV_NGI Sum of New and Current disaggregates 2015 400
PMTCT_ARV_NGI Sum of Regimen disaggregates 2015 448
PMTCT_EID By infants who received a virologic test within 2 months of birth 2015 150
PMTCT_EID By infants who received their first virologic HIV test between 2 and 12 months of age 2015 200
PMTCT_EID By infants with a positive virologic test result within 12 months of birth 2015 15
PMTCT_EID Number of HIV- positive pregnant women identified during the reporting period (include known HIV-positive women at entry into PMTCT) 2015 1,250
PMTCT_EID Number of infants who had a virologic HIV test within 12 months of birth during the reporting period 2015 350
PMTCT_EID Sum of Infant Age disaggregates 2015 350
PMTCT_STAT By: Known positives at entry 2015 290
PMTCT_STAT By: Number of new positives identified 2015 1,035
PMTCT_STAT Number of new ANC and L&D clients 2015 7,200
PMTCT_STAT Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results) 2015 6,490
PMTCT_STAT Sum of Positives Status disaggregates 2015 1,325
PMTCT_STAT_NGI By: Known positives at entry 2015 290
PMTCT_STAT_NGI By: Number of new positives identified 2015 1,035
PMTCT_STAT_NGI Number of new ANC and L&D clients 2015 7,200
PMTCT_STAT_NGI Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results) 2015 6,490
PMTCT_STAT_NGI Sum of Positives Status disaggregates 2015 1,325
SITE_SUPP By program area/support type: Care and Support Direct Service Delivery (DSD) 2015 35
SITE_SUPP By program area/support type: HTC Direct Service Delivery (DSD) 2015 43
SITE_SUPP By program area/support type: Lab Direct Service Delivery (DSD) 2015 12
SITE_SUPP By program area/support type: PHDP/Family Planning & Integration Direct Service Delivery (DSD) 2015 10
SITE_SUPP By program area/support type: PMTCT Direct Service Delivery (DSD) 2015 33
SITE_SUPP By program area/support type: TB/HIV Direct Service Delivery (DSD) 2015 35
SITE_SUPP By program area/support type: Treatment Direct Service Delivery (DSD) 2015 35
SITE_SUPP By program area/support type: VMMC Direct Service Delivery (DSD) 2015 27
SITE_SUPP Number of unique sites supported by PEPFAR 2015 43
TB_ART Age: 0-4 2015 6
TB_ART Age: 15+ 2015 313
TB_ART Age: 5-14 2015 81
TB_ART Aggregated Age: <15 2015 87
TB_ART Aggregated Age: 15+ 2015 313
TB_ART Female 2015 280
TB_ART Known HIV-positive 2015 50
TB_ART Male 2015 120
TB_ART Newly tested 2015 350
TB_ART Sum of Aggregated Age disaggregates 2015 400
TB_ART Sum of Sex disaggregates 2015 400
TB_ART Sum of Test Status disaggregates 2015 400
TB_ART The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period 2015 550
TB_ART The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period 2015 400
TX_CURR Age/Sex: <1 Female 2015 10
TX_CURR Age/Sex: <1 Female 2015 10
TX_CURR Age/Sex: <1 Male 2015 10
TX_CURR Age/Sex: <1 Male 2015 10
TX_CURR Age/Sex: 1-4 Female 2015 100
TX_CURR Age/Sex: 1-4 Female 2015 100
TX_CURR Age/Sex: 1-4 Male 2015 80
TX_CURR Age/Sex: 1-4 Male 2015 80
TX_CURR Age/Sex: 15+ Female 2015 4,990
TX_CURR Age/Sex: 15+ Female 2015 4,990
TX_CURR Age/Sex: 15+ Male 2015 4,695
TX_CURR Age/Sex: 15+ Male 2015 4,695
TX_CURR Age/Sex: 5-14 Female 2015 165
TX_CURR Age/Sex: 5-14 Female 2015 165
TX_CURR Age/Sex: 5-14 Male 2015 150
TX_CURR Age/Sex: 5-14 Male 2015 150
TX_CURR Aggregated Age/Sex: <1 Female 2015 10
TX_CURR Aggregated Age/Sex: <1 Female 2015 10
TX_CURR Aggregated Age/Sex: <1 Male 2015 10
TX_CURR Aggregated Age/Sex: <1 Male 2015 10
TX_CURR Aggregated Age/Sex: <15 Female 2015 275
TX_CURR Aggregated Age/Sex: <15 Female 2015 275
TX_CURR Aggregated Age/Sex: <15 Male 2015 240
TX_CURR Aggregated Age/Sex: <15 Male 2015 240
TX_CURR Aggregated Age/Sex: 15+ Female 2015 4,990
TX_CURR Aggregated Age/Sex: 15+ Female 2015 4,990
TX_CURR Aggregated Age/Sex: 15+ Male 2015 4,695
TX_CURR Aggregated Age/Sex: 15+ Male 2015 4,695
TX_CURR Number of adults and children receiving antiretroviral therapy (ART) 2015 10,200
TX_CURR Number of adults and children receiving antiretroviral therapy (ART) 2015 10,200
TX_CURR Percent children with advanced HIV infection receiving antiretroviral therapy (ART) [CURRENT] 2015 5
TX_CURR Percent women and girls with advanced HIV infection receiving antiretroviral therapy (ART) [CURRENT] 2015 52
TX_CURR Sum of age/sex disaggregates 2015 515
TX_CURR Sum of Age/Sex disaggregations 2015 515
TX_CURR Sum of Aggregated Age/Sex <15 2015 515
TX_CURR Sum of Aggregated Age/Sex <15 2015 515
TX_CURR Sum of Aggregated Age/Sex 15+ 2015 9,685
TX_CURR Sum of Aggregated Age/Sex 15+ 2015 9,685
TX_CURR Sum of Aggregated Age/Sex disaggregates 2015 10,200
TX_CURR Sum of Aggregated Age/Sex disaggregates 2015 10,200
TX_CURR_NGI Age/Sex: <1 Female 2015 10
TX_CURR_NGI Age/Sex: <1 Male 2015 10
TX_CURR_NGI Age/Sex: 1-4 Female 2015 100
TX_CURR_NGI Age/Sex: 1-4 Male 2015 80
TX_CURR_NGI Age/Sex: 15+ Female 2015 4,990
TX_CURR_NGI Age/Sex: 15+ Male 2015 4,695
TX_CURR_NGI Age/Sex: 5-14 Female 2015 165
TX_CURR_NGI Age/Sex: 5-14 Male 2015 150
TX_CURR_NGI Aggregated Age/Sex: <1 Female 2015 10
TX_CURR_NGI Aggregated Age/Sex: <1 Male 2015 10
TX_CURR_NGI Aggregated Age/Sex: <15 Female 2015 275
TX_CURR_NGI Aggregated Age/Sex: <15 Male 2015 240
TX_CURR_NGI Aggregated Age/Sex: 15+ Female 2015 4,990
TX_CURR_NGI Aggregated Age/Sex: 15+ Male 2015 4,695
TX_CURR_NGI Number of adults and children receiving antiretroviral therapy (ART) 2015 10,200
TX_CURR_NGI Sum of Age/Sex disaggregates 2015 10,200
TX_CURR_NGI Sum of Aggregated Age/Sex <15 2015 515
TX_CURR_NGI Sum of Aggregated Age/Sex 15+ 2015 9,685
TX_CURR_NGI Sum of Aggregated Age/Sex disaggregates 2015 10,200
TX_NEW Aggregated Grouping by Age: <1 Male 2015 10
TX_NEW Aggregated Grouping by Age/Sex: <1 Female 2015 45
TX_NEW Aggregated Grouping by Age/Sex: <15 Female 2015 890
TX_NEW Aggregated Grouping by Age/Sex: <15 Male 2015 185
TX_NEW Aggregated Grouping by Age/Sex: 15+ Female 2015 3,270
TX_NEW Aggregated Grouping by Age/Sex: 15+ Male 2015 655
TX_NEW Breastfeeding status 2015 350
TX_NEW By Age/Sex: <1 Female 2015 45
TX_NEW By Age/Sex: <1 Male 2015 10
TX_NEW By Age/Sex: 1-4 Female 2015 115
TX_NEW By Age/Sex: 1-4 Male 2015 25
TX_NEW By Age/Sex: 10-14 Female 2015 570
TX_NEW By Age/Sex: 10-14 Male 2015 115
TX_NEW By Age/Sex: 15-19 Female 2015 590
TX_NEW By Age/Sex: 15-19 Male 2015 115
TX_NEW By Age/Sex: 20-24 Female 2015 865
TX_NEW By Age/Sex: 20-24 Male 2015 180
TX_NEW By Age/Sex: 25-49 Female 2015 1,725
TX_NEW By Age/Sex: 25-49 Male 2015 335
TX_NEW By Age/Sex: 5-9 Female 2015 160
TX_NEW By Age/Sex: 5-9 Male 2015 35
TX_NEW By Age/Sex: 50+ Female 2015 90
TX_NEW By Age/Sex: 50+ Male 2015 25
TX_NEW Number of adults and children newly enrolled on antiretroviral therapy (ART) 2015 5,000
TX_NEW Pregnancy status 2015 1,100
TX_NEW Sum of Age/Sex disaggregates 2015 5,000
TX_NEW Sum of Aggregated Age/Sex disaggregates 2015 5,000
TX_RET Age: 0-4 (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART) 2015 300
TX_RET Age: 15+ (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART) 2015 1,900
TX_RET Age: 5-14 (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART) 2015 800
TX_RET Aggregated Age: <15 (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART) 2015 1,100
TX_RET Aggregated Age: 15+ (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART) 2015 1,900
TX_RET Number of adults and children who are still alive and on treatment at 12 months after initiating ART 2015 2,800
TX_RET Pregnancy and breastfeeding status (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART) 2015 600
TX_RET Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up 2015 3,000
TX_RET_den Age: 0-4 (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) 2015 300
TX_RET_den Age: 15+ (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) 2015 1,800
TX_RET_den Age: 5-14 (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) 2015 700
TX_RET_den Aggregated Age: <15 (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) 2015 1,000
TX_RET_den Aggregated Age: 15+ (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) 2015 1,800
TX_RET_den Pregnancy and breastfeeding status (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) 2015 700
VMMC_AE By AE Type: Number of VMMC clients with one or more moderate or severe surgical post-operative AE(s) 2015 25
VMMC_AE Number of males circumcised surgically or by medical device that experienced at least one moderate or severe adverse event(s) (AEs) 2015 25
VMMC_AE Sub-Disag: By Surgical post-operative AE(s) by maximum severity category: Number of clients with one or more moderate surgical post-operative AE(s), but no severe surgical post-operative AE(s) 2015 25
VMMC_CIRC By Age: 10-14 2015 868
VMMC_CIRC By Age: 10-14 2015 96
VMMC_CIRC By Age: 15-19 2015 420
VMMC_CIRC By Age: 15-19 2015 44
VMMC_CIRC By Age: 20-24 2015 465
VMMC_CIRC By Age: 20-24 2015 49
VMMC_CIRC By Age: 25-49 2015 370
VMMC_CIRC By Age: 25-49 2015 44
VMMC_CIRC By Age: 50+ 2015 127
VMMC_CIRC By Age: 50+ 2015 17
VMMC_CIRC By circumcision technique: Surgical VMMC 2015 2,250
VMMC_CIRC By circumcision technique: Surgical VMMC 2015 250
VMMC_CIRC By follow-up status: Number of surgically circumcised clients who did NOT return for follow-up care within 14 days of circumcision surgery 2015 400
VMMC_CIRC By follow-up status: Number of surgically circumcised clients who did NOT return for follow-up care within 14 days of circumcision surgery 2015 100
VMMC_CIRC By follow-up status: Number of surgically circumcised clients who returned at least once for follow-up care within 14 days of circumcision surgery 2015 1,830
VMMC_CIRC By follow-up status: Number of surgically circumcised clients who returned at least once for follow-up care within 14 days of circumcision surgery 2015 150
VMMC_CIRC By HIV status: Number of clients with undocumented/indeterminate HIV status or not tested for HIV at site 2015 120
VMMC_CIRC By HIV status: Number of clients with undocumented/indeterminate HIV status or not tested for HIV at site 2015 33
VMMC_CIRC By HIV status: Number of HIV-negative clients (tested HIV negative at VMMC program) 2015 1,973
VMMC_CIRC By HIV status: Number of HIV-negative clients (tested HIV negative at VMMC program) 2015 174
VMMC_CIRC By HIV status: Number of HIV-positive clients (tested HIV positive at VMMC site) 2015 157
VMMC_CIRC By HIV status: Number of HIV-positive clients (tested HIV positive at VMMC site) 2015 43
VMMC_CIRC Number of males circumcised as part of the voluntary medical male circumcision (VMMC) for HIV prevention program within the reporting period 2015 2,250
VMMC_CIRC Number of males circumcised as part of the voluntary medical male circumcision (VMMC) for HIV prevention program within the reporting period 2015 250
VMMC_CIRC Sum of age disaggregates 2015 250
VMMC_CIRC Sum of Age disaggregations 2015 2,250
VMMC_CIRC_NGI By Age: 10-14 2015 964
VMMC_CIRC_NGI By Age: 15-19 2015 464
VMMC_CIRC_NGI By Age: 20-24 2015 514
VMMC_CIRC_NGI By Age: 25-49 2015 414
VMMC_CIRC_NGI By Age: 50+ 2015 144
VMMC_CIRC_NGI By circumcision technique: Surgical VMMC 2015 2,500
VMMC_CIRC_NGI By follow-up status: Number of surgically circumcised clients who did NOT return for follow-up care within 14 days of circumcision surgery 2015 534
VMMC_CIRC_NGI By follow-up status: Number of surgically circumcised clients who returned at least once for follow-up care within 14 days of circumcision surgery 2015 1,916
VMMC_CIRC_NGI By HIV status: Number of clients with undocumented/indeterminate HIV status or not tested for HIV at site 2015 142
VMMC_CIRC_NGI By HIV status: Number of HIV-negative clients (tested HIV negative at VMMC program) 2015 2,109
VMMC_CIRC_NGI By HIV status: Number of HIV-positive clients (tested HIV positive at VMMC site) 2015 199
VMMC_CIRC_NGI Number of males circumcised as part of the voluntary medical male circumcision (VMMC) for HIV prevention program within the reporting period 2015 2,500
VMMC_CIRC_NGI Sum of Age disaggregates 2015 2,500
Key Issues Identified in Mechanism
Military Populations
Mobile Populations
Safe Motherhood
Tuberculosis
Family Planning